Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark
René Cordtz, Salome Kristensen, Louise Plank Holm Dalgaard, Rasmus Westermann, Kirsten Duch, Jesper Lindhardsen, Christian Torp-Pedersen, Lene Dreyer
Journal of Clinical Medicine, doi:10.3390/jcm10173842
Background: Patients with systemic lupus erythematosus (SLE) have an increased risk of infections due to impaired immune functions, disease activity, and treatment. This study investigated the impact of having SLE on the incidence of hospitalisation with COVID-19 infection. Methods: This was a nationwide cohort study from Denmark between 1 March 2020 to 2 February 2021, based on the linkage of several nationwide registers. The adjusted incidence of COVID-19 hospitalisation was estimated for patients with SLE compared with the general population in Cox-regression models. Among SLE patients, the hazard ratio (HR) for hospitalisation was analysed as nested case-control study. Results: Sixteen of the 2533 SLE patients were hospitalised with COVID-19 infection. The age-sex adjusted rate per 1000 person years was 6.16 (95% CI 3.76-10.08) in SLE patients, and the corresponding hazard ratio was 2.54 (95% CI 1.55-4.16) compared with the matched general population group after adjustment for comorbidities. Among SLE patients, hydroxychloroquine treatment was associated with a HR for hospitalisation of 0.61 (95% CI 0.19-1.88), and 1.06 (95% CI 0.3-3.72) for glucocorticoid treatment. Conclusion: Patients with SLE were at increased risk of hospitalisation with COVID-19.
References
Bodilsen, Leth, Nielsen, Holler, Benfield et al., Positive Predictive Value of ICD-10 Diagnosis Codes for COVID-19, Clin. Epidemiol,
doi:10.2147/CLEP.S309840Cassione, Zanframundo, Biglia, Codullo, Montecucco et al., COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine, Ann. Rheum. Dis,
doi:10.1136/annrheumdis-2020-217717Chuah, Teh, Akbar, Cheong, Singh, Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): Report from a tertiary hospital during the peak of the pandemic, Ann. Rheum. Dis,
doi:10.1136/annrheumdis-2020-218475Cordtz, Lindhardsen, Soussi, Vela, Uhrenholt et al., Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: A nationwide cohort study from Denmark, Rheumatology,
doi:10.1093/rheumatology/keaa897Danza, Ruiz-Irastorza, Infection risk in systemic lupus erythematosus patients: Susceptibility factors and preventive strategies, Lupus,
doi:10.1177/0961203313493032Fosbøl, Butt, Østergaard, Andersson, Selmer et al., Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality, JAMA-J. Am. Med. Assoc,
doi:10.1001/jama.2020.11301Geleris, Sun, Platt, Zucker, Baldwin et al., Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, N. Engl. J. Med
Gianfrancesco, Hyrich, Al-Adely, Carmona, Danila et al., Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann. Rheum. Dis,
doi:10.1136/annrheumdis-2020-217871Glintborg, Jensen, Engel, Terslev, Jensen et al., Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: Results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registry, RMD Open,
doi:10.1136/rmdopen-2020-001505Hermansen, Lindhardsen, Torp-Pedersen, Faurschou, Jacobsen, Incidence of Systemic Lupus Erythematosus and Lupus Nephritis in Denmark: A Nationwide Cohort Study, J. Rheumatol,
doi:10.3899/jrheum.151221Johannesdottir, Horváth-Puhó, Ehrenstein, Schmidt, Pedersen et al., Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions, Clin. Epidemiol,
doi:10.2147/CLEP.S37587Konig, Kim, Scheetz, Graef, Liew et al., Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19, Ann. Rheum. Dis,
doi:10.1136/annrheumdis-2020-217690Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov,
doi:10.1038/s41421-019-0132-8Mageau, Aldebert, Van Gysel, Papo, Timsit et al., SARS-CoV-2 infection among inpatients with systemic lupus erythematosus in France: A nationwide epidemiological study, Ann. Rheum. Dis,
doi:10.1136/annrheumdis-2021-220010Manzano, Fernández-Bello, Sanz, Marhuenda, López-Longo et al., Insights into the Procoagulant Profile of Patients with Systemic Lupus Erythematosus without Antiphospholipid Antibodies, J. Clin. Med,
doi:10.3390/jcm9103297Mathian, Mahevas, Rohmer, Roumier, Cohen-Aubart et al., Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine, Ann. Rheum. Dis,
doi:10.1136/annrheumdis-2020-217566Ramirez, Gerosa, Beretta, Bellocchi, Argolini et al., COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients, Semin. Arthritis Rheum,
doi:10.1016/j.semarthrit.2020.06.012Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State, JAMA,
doi:10.1001/jama.2020.8630Schmidt, Schmidt, Sandegaard, Ehrenstein, Pedersen et al., The Danish National Patient Registry: A review of content, data quality, and research potential, Clin. Epidemiol,
doi:10.2147/CLEP.S91125Smeele, Perez-Garcia, Grimminck, Schoenmakers, Mulders et al., Systemic lupus erythematosus and COVID-19 during pregnancy, Lupus,
doi:10.1177/09612033211002270Zurita, Arreaga, Chavez, Zurita, SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador after Prior Treatment with Hydroxychloroquine for Systemic Lupus Erythematosus, Am. J. Case Rep,
doi:10.12659/AJCR.927304
